

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

(Amendment No. 10)\*

**ANI Pharmaceuticals, Inc.**

---

(Name of Issuer)

**Common Stock, \$0.0001 par value per share**

---

(Title of Class of Securities)

**00182C103**

---

(CUSIP Number)

**Robert A. Graham, MVP Capital  
259 N. Radnor-Chester Road, Suite 130  
Radnor, PA, 19087  
(610) 254-2999**

---

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**08/21/2025**

---

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

**CUSIP No.** 00182C103

Name of reporting person

1 Meridian Venture Partners II GP, L.P. ("GP")

2 Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only  
Source of funds (See Instructions)

4 OO  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

1,014,381.00

Owned by

Sole Dispositive Power

Each

9

0.00

Reporting

Person

With:

Shared Dispositive Power

10

1,014,381.00

Aggregate amount beneficially owned by each reporting person

11 1,014,381.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 4.7 %

Type of Reporting Person (See Instructions)

14 PN

## SCHEDULE 13D

**CUSIP No.** 00182C103

Name of reporting person

1 Meridian Venture Partners II, L.P.

Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 OO  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

Number of 7 Sole Voting Power

Shares	
Beneficially	0.00
Owned by	Shared Voting Power
Each	8
Reporting	1,014,381.00
Person	Sole Dispositive Power
With:	9
	0.00
	Shared Dispositive Power
	10
	1,014,381.00
	Aggregate amount beneficially owned by each reporting person
11	1,014,381.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>
	Percent of class represented by amount in Row (11)
13	4.7 %
	Type of Reporting Person (See Instructions)
14	PN

## SCHEDULE 13D

**CUSIP No.** 00182C103

1	Name of reporting person
	Meridian Venture Partners II, Co.
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	SEC use only
	Source of funds (See Instructions)
4	OO
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	<input type="checkbox"/>
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
7	0.00
	Shared Voting Power
Number of	8
Shares	1,014,381.00
Beneficially	Sole Dispositive Power
Owned by	9
Each	0.00
Reporting	Shared Dispositive Power
Person	10
With:	1,014,381.00
11	Aggregate amount beneficially owned by each reporting person

1,014,381.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

4.7 %

Type of Reporting Person (See Instructions)

14

CO

### SCHEDULE 13D

**CUSIP No.** 00182C103

Name of reporting person

1

Robert E. Brown, Jr.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

OO

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

UNITED STATES

Sole Voting Power

7

20,189.00

Number of Shares

Shared Voting Power

Beneficially 8

1,014,381.00

Owned by

Sole Dispositive Power

Each

9

20,189.00

Reporting Person

With:

Shared Dispositive Power

10

1,014,381.00

Aggregate amount beneficially owned by each reporting person

11

1,034,570.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

4.8 %

Type of Reporting Person (See Instructions)

14

IN

# SCCHEDULE 13D

## Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, \$0.0001 par value per share

Name of Issuer:

(b)

ANI Pharmaceuticals, Inc.

Address of Issuer's Principal Executive Offices:

(c)

210 Main Street West, Baudette, MINNESOTA , 56623.

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Meridian Venture Partners II GP, L.P. ("GP")

Signature: /s/ Robert E. Brown, Jr.

Name/Title: Robert E. Brown, Jr.

Date: 08/21/2025

Meridian Venture Partners II, L.P.

Signature: /s/ Robert E. Brown, Jr.

Name/Title: Robert E. Brown, Jr.

Date: 08/21/2025

Meridian Venture Partners II, Co.

Signature: /s/ Robert E. Brown, Jr.

Name/Title: Robert E. Brown, Jr.

Date: 08/21/2025

Robert E. Brown, Jr.

Signature: /s/ Robert E. Brown, Jr.

Name/Title: Robert E. Brown, Jr.

Date: 08/21/2025